3 June 2021
Longevity briefs provides a short summary of novel research in biology, medicine, or biotechnology that caught the attention of our researchers in Oxford, due to its potential to improve our health, wellbeing, and longevity.
Dr. Greg Fahy is a world renowned cryobiologist and is also the chief science officer, and co-founder, of Intervene Immune, a company which pioneers treatments for thymus regeneration and age-related immune system decline. In this short exert from our interview, Dr. Fahy talks about his pilot study, Thymic Rejuvenation and Immunorestoration and Insulin Mitigation, or the TRIIM trial.
This trial was initially designed to test whether a cocktail of DHEA, metformin and growth hormone could rejuvenate the thymus. On further inspection, the team made the ground-breaking discovery, that the drug cocktail had wound back the biological age of the participants.
In the full talk, Dr. Fahy discusses the groundbreaking moment they discovered the results of the TRIIM trial and whether they constitute true ageing reversal. He also delves into the details of TRIIM-X trial, changes to the protocol, going international and what success might look like.